Notably, essential information relevant to the use of mTOR inhibitors in endometriosis patients is lacking, including their potential to improve hormone resistance in oestrogen-dependent diseases (e.g. breast and endometrial cancers), their application as immunosuppressants, their role in enhancing fertility in women seeking pregnancy, and effective toxicity management in clinical settings. This evidence concerns the gene MTOR and endometrial cancer.